CN102365097A - 艰难梭菌毒素的抗体 - Google Patents

艰难梭菌毒素的抗体 Download PDF

Info

Publication number
CN102365097A
CN102365097A CN2010800086731A CN201080008673A CN102365097A CN 102365097 A CN102365097 A CN 102365097A CN 2010800086731 A CN2010800086731 A CN 2010800086731A CN 201080008673 A CN201080008673 A CN 201080008673A CN 102365097 A CN102365097 A CN 102365097A
Authority
CN
China
Prior art keywords
toxin
difficile
clostridium difficile
antibodies
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2010800086731A
Other languages
English (en)
Chinese (zh)
Inventor
克利福德·肖恩
约翰·兰登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BMH
Micropharm Ltd
Original Assignee
Health Protection Agency
Micropharm Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0902851A external-priority patent/GB0902851D0/en
Priority claimed from GB0916153A external-priority patent/GB0916153D0/en
Application filed by Health Protection Agency, Micropharm Ltd filed Critical Health Protection Agency
Publication of CN102365097A publication Critical patent/CN102365097A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN2010800086731A 2009-02-20 2010-02-19 艰难梭菌毒素的抗体 Pending CN102365097A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0902851.5 2009-02-20
GB0902851A GB0902851D0 (en) 2009-02-20 2009-02-20 Antibodies to clostridium difficile toxins
GB0916153A GB0916153D0 (en) 2009-09-15 2009-09-15 Antibodies to clostridium difficile toxins
GB0916153.0 2009-09-15
PCT/GB2010/050288 WO2010094970A1 (en) 2009-02-20 2010-02-19 Antibodies to clostridium difficile toxins

Publications (1)

Publication Number Publication Date
CN102365097A true CN102365097A (zh) 2012-02-29

Family

ID=42109880

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2010800086731A Pending CN102365097A (zh) 2009-02-20 2010-02-19 艰难梭菌毒素的抗体

Country Status (7)

Country Link
US (2) US8709428B2 (enExample)
EP (1) EP2405940B1 (enExample)
JP (1) JP5740714B2 (enExample)
CN (1) CN102365097A (enExample)
AU (1) AU2010215275B2 (enExample)
CA (1) CA2752815A1 (enExample)
WO (1) WO2010094970A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法
CN105555309A (zh) * 2013-04-19 2016-05-04 英穆伦有限公司 治疗和/或预防艰难梭菌相关疾病的方法和组合物
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection
US8431361B2 (en) * 2010-09-17 2013-04-30 Board Of Regents Of The University Of Oklahoma Bacterial cells, optimized nucleotide sequences and methods for improved expression of recombinant Clostridium difficile toxin B
MX391236B (es) * 2011-04-22 2025-03-21 Wyeth Llc Composiciones relacionadas con una toxina de clostridium difficile mutante y sus metodos.
GB201110712D0 (en) 2011-06-23 2011-08-10 Univ Ulster Diagnostic methods
WO2013038156A1 (en) * 2011-09-16 2013-03-21 Ucb Pharma S.A. Neutralising antibodies to the major exotoxins tcda and tcdb of clostridium difficile
CA2856085C (en) 2011-11-18 2020-06-30 National Research Council Of Canada Clostridium difficile lipoteichoic acid and uses thereof
SG11201402375VA (en) 2011-12-08 2014-10-30 Novartis Ag Clostridium difficile toxin-based vaccine
DE102011121237A1 (de) * 2011-12-14 2013-06-20 Universitätsklinikum Hamburg-Eppendorf Einzeldomänen-Antikörper gegen Clostridium difficile Toxin CDTa
AR089797A1 (es) * 2012-01-27 2014-09-17 Merck Sharp & Dohme Vacunas contra clostridum difficile que comprenden toxinas recombinantes
RU2628305C2 (ru) 2012-03-02 2017-08-15 Регенерон Фармасьютиказ, Инк. Человеческие антитела к токсинам clostridium difficile
EP2921502A4 (en) 2012-10-19 2016-09-28 Evec Inc AGAINST TOXIN FROM CLOSTRIDIUM DIFFICILE OR ANTIGENBINDING FRAGMENT SPECIFIC HUMAN ANTIBODY
BR122016023101B1 (pt) 2012-10-21 2022-03-22 Pfizer Inc Polipeptídeo, composição imunogênica que o compreende, bem como célula recombinante derivada de clostridium difficile
US9493518B2 (en) * 2013-03-14 2016-11-15 National Health Research Institutes Compositions and methods for treating clostridium difficile-associated diseases
CN103665141B (zh) * 2013-12-31 2015-09-16 北京大学 与艰难梭菌细胞毒素b相互作用的蛋白
WO2015150493A1 (en) * 2014-04-01 2015-10-08 Institut Pasteur Predictive value of clostridium difficile-specific immune response for recurrence and disease outcome
EP3344276B1 (en) 2015-09-03 2020-04-22 The Board of Regents of the University of Oklahoma Peptide inhibitors of clostridium difficile tcdb toxin
USD952157S1 (en) 2020-06-19 2022-05-17 Qualigen Inc. Whole blood treatment cartridge

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044402A1 (en) * 1999-01-29 2000-08-03 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
WO2006071877A2 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
CN101014620A (zh) * 2004-02-06 2007-08-08 马萨诸塞州大学 抗艰难梭菌毒素抗体及其用途
CN101363867A (zh) * 2008-05-26 2009-02-11 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条、其制备方法及其应用

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS608225A (ja) 1983-06-29 1985-01-17 Kowa Co 腸管吸収医薬組成物
US5601823A (en) 1989-10-31 1997-02-11 Ophidian Pharmaceuticals, Inc. Avian antitoxins to clostridium difficle toxin A
AU702405B2 (en) 1994-09-06 1999-02-18 Immucell Corporation Therapeutic treatment of clostridium difficile associated diseases
US6096310A (en) 1997-04-15 2000-08-01 Bier; Milan Oral immunotherapy of bacterial overgrowth
AU746859B2 (en) 1997-06-20 2002-05-02 Imperial College Of Science, Technology And Medicine Immonogenic fragments of toxin a of clostridium difficile
DE69829400T2 (de) * 1997-10-20 2006-04-13 Acambis, Inc., Cambridge Passive immunisierung gegen durch clostridium difficile verursachte krankheit
US6969520B2 (en) 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
US6074689A (en) 1998-03-10 2000-06-13 Immucell Corporation Colonic delivery of protein or peptide compositions
US6673574B2 (en) 2000-11-30 2004-01-06 Unigene Laboratories Inc. Oral delivery of peptides using enzyme-cleavable membrane translocators
GB0205206D0 (en) 2002-03-06 2002-04-17 Oxoid Ltd Synthetic peptides
AU2003299527A1 (en) 2002-06-17 2004-06-07 Jimmy D. Ballard Mutant of clostridium difficile toxin b and methods of use
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
US7794721B2 (en) 2006-12-13 2010-09-14 Simon Michael R Synthesis of human secretory IgM and the treatment of clostridium difficile associated diseases herewith
GB0921288D0 (en) 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000044402A1 (en) * 1999-01-29 2000-08-03 Galagen, Inc. Pharmaceutical composition comprising a selected antigen and candida species antigen and methods
CN101014620A (zh) * 2004-02-06 2007-08-08 马萨诸塞州大学 抗艰难梭菌毒素抗体及其用途
WO2006071877A2 (en) * 2004-12-27 2006-07-06 Progenics Pharmaceuticals (Nevada), Inc. Orally deliverable and anti-toxin antibodies and methods for making and using them
CN101363867A (zh) * 2008-05-26 2009-02-11 北京庄笛浩禾生物医学科技有限公司 一种艰难梭菌a、b毒素胶体金检测试纸条、其制备方法及其应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EL-RASHDY M. REDWAN等: "Production and purification of ovine anti-tetanus antibody", 《COMPARATIVE IMMUNOLOGY, MICROBIOLOGY & INFECTIOUS DISEASES》, vol. 28, 31 December 2005 (2005-12-31), pages 167 - 176 *
王兴民等: "酶联免疫吸附试验检测艰难梭菌A毒素 ", 《微生物学免疫学进展》, vol. 24, no. 4, 31 December 1996 (1996-12-31) *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109776676A (zh) * 2012-11-28 2019-05-21 Cnj控股公司 针对艰难梭菌的抗体
CN105555309A (zh) * 2013-04-19 2016-05-04 英穆伦有限公司 治疗和/或预防艰难梭菌相关疾病的方法和组合物
CN105451762A (zh) * 2013-04-22 2016-03-30 俄克拉荷马州大学评议会 艰难梭菌疫苗及使用方法

Also Published As

Publication number Publication date
JP2012518624A (ja) 2012-08-16
US20120121607A1 (en) 2012-05-17
AU2010215275B2 (en) 2016-03-31
EP2405940A1 (en) 2012-01-18
CA2752815A1 (en) 2010-08-26
EP2405940B1 (en) 2021-08-04
US8709428B2 (en) 2014-04-29
US20150010580A1 (en) 2015-01-08
JP5740714B2 (ja) 2015-06-24
WO2010094970A1 (en) 2010-08-26
AU2010215275A1 (en) 2011-07-28

Similar Documents

Publication Publication Date Title
JP5740714B2 (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）毒素に対する抗体
JP6130622B2 (ja) クロストリジウムディフィシル疾患に対する受動免疫感作
Chen et al. Evaluation of purified UspA from Moraxella catarrhalis as a vaccine in a murine model after active immunization
US10259864B2 (en) Anti-campylobacter jejuni antibodies and uses therefor
Thammavongsa et al. Protein A-neutralizing monoclonal antibody protects neonatal mice against Staphylococcus aureus
CN102740889A (zh) 用于预防或抑制艰难梭菌感染的疗法
Katinger et al. Pigs aerogenously immunized with genetically inactivated (ghosts) or irradiated Actinobacillus pleuropneumoniae are protected against a homologous aerosol challenge despite differing in pulmonary cellular and antibody responses
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
Osek et al. Role of antibodies against biotype-specific Vibrio cholerae pili in protection against experimental classical and El Tor cholera
JP2000509961A (ja) 共通のブドウ球菌抗原と広範に反応するオプソニン作用性抗体
US11278609B2 (en) Polypeptides derived from Enterococcus and their use for vaccination and the generation of therapeutic antibodies
US9845350B2 (en) Monoclonal antibodies that react with the capsule of bacillus anthracis
EP4511059A1 (en) Streptococcus suis vaccine composition comprising immunogenic fusion polypeptides
Frey The localization of two epitopes recognized by the monoclonal antibody PCG-4 on toxin A of Clostridium difficile
JPH09301889A (ja) 合成ペプチドを含有する緑膿菌ワクチン及びそれから生産された治療剤

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20160926

Address after: London 79 Whitehall, Richmond building

Applicant after: BMH

Applicant after: Micropharm Limited

Address before: Wiltshire

Applicant before: Health Protection Agency

Applicant before: Micropharm Limited

RJ01 Rejection of invention patent application after publication

Application publication date: 20120229

RJ01 Rejection of invention patent application after publication